How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Expanding Seniors Access to Mental Health Services Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2025 · first_quarter · Q1
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Source: Senate LDA
Medicare Part B provisions relating to home infusion of IVIG. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Reserved for the Speaker.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Reserved for the Speaker.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing. Issues related to the funding of HHS blood and plasma awareness campaign.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates. Issues related to the funding of HHS blood and plasma awareness campaign.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Afghan Allies Protection Act of 2023
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Share the Savings with Seniors Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
PLASMA Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma.
Inflation Reduction Act of 2022
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma.
Inflation Reduction Act of 2022
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Inflation Reduction Act of 2022
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donotions.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donotions.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations. Issues relating to enactment of HR 7839, extension of the IVIG Demonstration project.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations. Issues relating to enactment of HR 7839, extension of the IVIG Demonstration project.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donotions.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donotions.
Continuing Access to In-Home IVIG Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations. Issues relating to enactment of HR 7839, extension of the IVIG Demonstration project.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy. Availability of plasma protein products, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy. Availability of plasma protein products, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy. Availability of plasma protein products, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations. Issues relating to Covid-19 vaccine priorities for donation center workers.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy. Availability of plasma protein products, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations. Issues relating to enactment of HR 7839, extension of the IVIG Demonstration project.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donotions.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donotions.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs.
Elijah E. Cummings Lower Drug Costs Now Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy.
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Safe Students Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Safe Students Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Protecting Americans from Tax Hikes (PATH) Act, sections pertaining to the Research and Development tax credit, and the Orphan Drug Tax Credit. HR 1.H.R.1 - An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018, sections pertaining to the Orphan Drug Tax Credit,
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. International Pricing Index. Reference pricing.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a demonstration project.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate.
American Health Care Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate.
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a demonstration project.
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues.
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs.
Medicare Part B Home Infusion Services Temporary Transitional Payment Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project.
Medicare Part B Improvement Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a demonstration project.
Safe Students Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a demonstration project.
Safe Students Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs.
Safe Students Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues.
Safe Students Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues.
Medicare IVIG Access Enhancement Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a demonstration project.
Medicare Home Infusion Therapy Access Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a demonstration project.
21st Century Cures Act
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
Protecting Americans from Tax Hikes (PATH) Act, sections pertaining to the Research and Development tax credit, and the Orphan Drug Tax Credit. HR 1.H.R.1 - An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018, sections pertaining to the Orphan Drug Tax Credit,
Veterans Back to Work Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
HR 1600 and HR 2999, Patients' Access to Treatments Act of 2017, pertaining to specialty insurance tiers. The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
Veterans Back to Work Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
Veterans Back to Work Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
Veterans Back to Work Act of 2017
Client: PLASMA PROTEIN THERAPEUTICS ASSOCIATION · Firm: PLASMA PROTEIN THERAPEUTICS ASSOCIATION
HR 1600 and HR 2999, Patients' Access to Treatments Act of 2017, pertaining to specialty insurance tiers. The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2024 · fourth_quarter · Q4
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2024 · third_quarter · Q3
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2024 · second_quarter · Q2
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2024 · first_quarter · Q1
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2023 · fourth_quarter · Q4
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates and HR 6465, The PLASMA Act.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2023 · third_quarter · Q3
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing including Part D rebates. Issues related to the funding of HHS blood and plasma awareness campaign.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2023 · second_quarter · Q2
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them, and the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to reference pricing systems. Inflation Reduction Act and negotiation provisions for plasma derived therapies. Funding for HHS Blood and Plasma Awareness Campaign.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to reference pricing systems. Issues relating to Source plasma donation and plasma protein products. The Inflation Reduction Act and provisions relating to plasma derived therapies and drug pricing. Issues related to the funding of HHS blood and plasma awareness campaign.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2023 · first_quarter · Q1
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2022 · fourth_quarter · Q4
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients. Inflation Reduction Act and negotiation provisions for plasma derived therapies.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma. The Inflation Reduction Act and provisions relating to exempting plasma derived therapies from direct negotiations
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2022 · third_quarter · Q3
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2022 · second_quarter · Q2
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376, Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products. Activity relating to cross border donation of plasma.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and HR 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products. Activity related to cross border donation of plasma and impact on patients.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2022 · first_quarter · Q1
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress. Activity related to cross border donation of plasma and impact on patients.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376 Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress. Activity relating to cross border donation of plasma.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2021 · fourth_quarter · Q4
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and the Build Back Better Act provisions related to drug pricing. . Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress. Activity related to cross border donation of plasma and impact on patients.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare and HR 5376 Build Back Better Act provisions related to drug pricing. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress. Activity relating to cross border donation of plasma.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2021 · third_quarter · Q3
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD and H.R. 3808. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress. Activity relating to cross border donation of plasma.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress. Activity related to cross border donation of plasma and impact on patients.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2021 · second_quarter · Q2
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress. Activity related to cross border donation of plasma and impact on patients.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress. Activity relating to cross border donation of plasma.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2021 · first_quarter · Q1
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress.
Education visits to House and Senate offices relating to plasma protein therapies and the rare disease patients that use them and the economic value as well as the need for continued Source plasma donations. The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B provisions relating to home infusion of IVIG, particularly in CIPD. CMS programs relating to proposed rules, including most favored nation and international pricing index and use of foreign reference pricing. HCR that moves U.S. towards single decisionmakers and government negotiations. HR 3 Lowering Drug Costs Now Act provisions relating to drug reimbursement in Medicare. Issues relating to COVID and plasma protein products and 116th Congress "Plasma Donation Awareness Act" and reintroduction in 117th Congress.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2020 · fourth_quarter · Q4
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy. Availability of plasma protein products, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations. Issues relating to Covid-19 vaccine priorities for donation center workers.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations. Issues relating to enactment of HR 7839, extension of the IVIG Demonstration project.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2020 · third_quarter · Q3
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy. Availability of plasma protein products, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donotions.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2020 · second_quarter · Q2
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy. Availability of plasma protein products, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donations.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing and plasma center donotions.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2020 · first_quarter · Q1
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy. Availability of plasma protein products, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS, specifically home infusion of plasma protein products during the Covid-19 pandemic. Issues relating to availability of plasma donation center testing.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2019 · fourth_quarter · Q4
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs. Issues relating to access of plasma protein products by HHS and CMS.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2019 · third_quarter · Q3
The Affordable Care Act, provisions relating to essential health benefits and patient protections. Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, HR 2905, Medicare IVIG Enhancement Act relating to payment for immunoglobulin for home infusion, H.R. 3 - Lower Drug Costs Now Act of 2019, sections relating to drug reimbursement and pricing programs.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2019 · second_quarter · Q2
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2019 · first_quarter · Q1
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues. Issues and comments related to CMS-5528-ANPRM and HHS proposed rule :Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2018 · fourth_quarter · Q4
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs. Part B to D issues.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. International Pricing Index. Reference pricing.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2018 · third_quarter · Q3
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project. HHS "American Patients First" request for information relating to Part B programs, essential health benefits, competitive acquisition programs and 340B discount programs.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2018 · second_quarter · Q2
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a IVIG demonstration project.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2018 · first_quarter · Q1
Protecting Americans from Tax Hikes (PATH) Act, sections pertaining to the Research and Development tax credit, and the Orphan Drug Tax Credit. HR 1.H.R.1 - An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018, sections pertaining to the Orphan Drug Tax Credit,
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2017 · fourth_quarter · Q4
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R. 3823, the Disaster Tax Relief and Airport and Airway Extension Act of 2017 - Section 302 including the extension of the Medicare Patient Intravenous Immunoglobin (IVIG) Access Demonstration Project.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2017 · third_quarter · 3A
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R. 3823, the Disaster Tax Relief and Airport and Airway Extension Act of 2017 - Section 302 including the extension of the Medicare Patient Intravenous Immunoglobin (IVIG) Access Demonstration Project.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2017 · second_quarter · 2A
HR 1600 and HR 2999, Patients' Access to Treatments Act of 2017, pertaining to specialty insurance tiers. The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2017 · first_quarter · 1A
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2017 · third_quarter · Q3
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R. 3823, the Disaster Tax Relief and Airport and Airway Extension Act of 2017 - Section 302 including the extension of the Medicare Patient Intravenous Immunoglobin (IVIG) Access Demonstration Project.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2017 · second_quarter · Q2
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.
HR 1600 and HR 2999, Patients' Access to Treatments Act of 2017, pertaining to specialty insurance tiers. The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2017 · first_quarter · Q1
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2016 · fourth_quarter · 4A
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2016 · third_quarter · 3A
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2016 · second_quarter · 2A
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2016 · first_quarter · 1A
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2016 · fourth_quarter · Q4
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM.HR 34, 21st Century Cures Act, sections relating to DME Competitive Bidding and Infusion Drugs
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2016 · third_quarter · Q3
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2016 · second_quarter · Q2
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2016 · first_quarter · Q1
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM. HRSA NPRM RELATED TO PART B REIMBURSEMENT MODEL.
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS AND PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS SUBMITTED TO CMS AND HRSA RELATING TO HRSA AND 340B PROGRAM. NPRM CONCERNING PART B REIMBURSEMENT.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2015 · third_quarter · 3A
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, HR 6; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, HR 275 ISSUES RELATING TO COMPETITIVE BIDDING OF DME INFUSION DRUGS
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2015 · fourth_quarter · 4A
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2015 · fourth_quarter · Q4
HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S.275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, S. 275; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, COMMENTS RELATING TO HRSA AND 340B PROGRAM
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2015 · third_quarter · Q3
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, HR 6; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT, HR 275 ISSUES RELATING TO COMPETITIVE BIDDING OF DME INFUSION DRUGS
Filing targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2015 · second_quarter · Q2
HR 1600; SECTIONS RELATING TO SPECIALTY TIERS, HR 2570; RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, HR 6; SECTIONS RELATING TO COMPETITIVE BIDDING OF INFUSION PUMPS AND DRUGS, ISSUES RELATING TO ORPHAN DRUG DESIGNATIONS, FDA/OMNIBUS APPROPRIATIONS PROVISIONS RELATING TO PLASMA PROTEIN THERAPIES, AFFORDABLE CARE ACT, MEDICARE REIMBURSEMENT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2015 · second_quarter · RA
Medicare reimbursement, orphan exemption to the annual pharmaceutical fee, orphan drug tax credit, 340B
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2014 · third_quarter · 3A
Medicare reimbursement, orphan exemption to the annual pharmaceutical fee, orphan drug tax credit, 340B
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2014 · fourth_quarter · 4A
orphan exemption to the annual pharmaceutical fee, issues relating to orphan drug designation, FDA/Omnibus Appropriations provisions relating to plasma protein therapies, Affordable Care Act, Medicare reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2014 · fourth_quarter · Q4
orphan exemption to the annual pharmaceutical fee, issues relating to orphan drug designation, FDA/Omnibus Appropriations provisions relating to plasma protein therapies, Affordable Care Act, Medicare reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2014 · third_quarter · Q3
Medicare reimbursement, orphan exemption to the annual pharmaceutical fee, orphan drug tax credit, 340B
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2014 · second_quarter · Q2
Medicare reimbursement, orphan exemption to the annual pharmaceutical fee, orphan drug tax credit, 340B, ACA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2014 · first_quarter · Q1
Medicare reimbursement, orphan exemption to the annual pharmaceutical fee, orphan drug tax credit, 340B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2013 · fourth_quarter · 4A
Medicare coverage and reimbursement of Part B drugs, orphan drug exclusion from the annual pharmaceutical fee established under the ACA, ACA implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2013 · fourth_quarter · Q4
Medicare coverage and reimbursement of Part B drugs, orphan drug exclusion from the annual pharmaceutical fee established under the ACA, ACA implementation.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2013 · third_quarter · Q3
Medicare coverage and reimbursement of Part B drugs, orphan drug exclusion from the annual pharmaceutical fee established in the ACA, ODA Tax Credit, ODA regulations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2013 · second_quarter · Q2
Medicare coverage of Part B drugs, orphan drug exclusion of the annual pharmaceutical fee established in the ACA, Orphan Drug Act tax credit, Medicare DME reimbursement, Orphan Drug Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2013 · first_quarter · Q1
Medicare coverage and reimbursement of Part B drugs, orphan drug exclusion from the annual pharmaceutical fee established in the ACA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2012 · fourth_quarter · Q4
Annual pharmaceutical fee, medicare coverage and reimbursement of Part B drugs, IRS annual pharmaceutical fee orphan drug exclusion, comparative effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2012 · third_quarter · 3A
Annual pharmaceutical fee, 340B discount drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, FDASIA, comparative effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2012 · third_quarter · 3A
Annual pharmaceutical fee, 340B discount drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, FDASIA, comparative effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2012 · third_quarter · Q3
Annual pharmaceutical fee, 340B drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, FDASIA, comparactive effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2012 · second_quarter · Q2
Annual pharmaceutical fee, 340B drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, PDUFA reauthorization legislation, comparative effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Internal Revenue Service (IRS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2012 · first_quarter · 1A
Annual pharmaceutical fee, 340B drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, drug shortages (PDUFA reauthorization), essential health benefits, comparative effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2012 · first_quarter · Q1
Annual pharmaceutical fee, 340B drug pricing program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, drug shortages (PDUFA reauthorization), essential health benefits, comparative effectiveness research
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · second_quarter · 2A
Annual pharmaceutical fee, 340B Drug Pricing Program, Medicare reimbursement under Part B, Orphan Drug Act, Accountable Care Organizations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · fourth_quarter · Q4
Annual pharmaceutical fee, 340B drug pricing program, Orphan Drug Act, Medicare Coverage and Reimbursement of Part B Drugs, Super Committee deficit reduction, drug shortages
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · third_quarter · 3A
Annual pharmaceutical fee, 340B Drug Pricing Program, Orphan Drug Act, Medicare coverage and reimbursement of Part B drugs, least costly alternative
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · third_quarter · Q3
Annual pharmaceutical fee, 340B Drug Pricing Program, Orphan Drug Act, Medicare Coverage and Reimbursement of Part B Drugs, Least Costly Alternative
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · second_quarter · 2A
Annual pharmaceutial fee, 340B Drug Pricing Program, Orphan Drug Act, Medicare Reimbursement of Part B drugs, Accountable Care Organizations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · first_quarter · 1A
Annual pharmaceutical fee, 340B Drug Pricing Program, Medicare reimbursement under Part B, Congressional briefing on the value of plasma protein therapies and the treatment of rare diseases
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · second_quarter · Q2
Annual pharmaceutical fee, 340B Drug Pricing Program, Orphan Drug Act, Medicare reimbursement of Part B drugs, Accountable Care Organizations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · first_quarter · Q1
Annual pharmaceutical fee, 340B Drug Pricing Program, Orphan Drug Act, Medicare reimbursement of Part B drugs, Accountable Care Organizations
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2011 · first_quarter · Q1
Annual pharmaceutical fee 340B Drug Pricing Program Medicare reimbursement of Part B drugs Congressional staff briefing on the value of plasma protein therapies in treating rare diseases
Filing targets: Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2010 · fourth_quarter · Q4
Medicare reimbursment and Medicare coverage decisions.
Annual fee for branded drugs manufacturers and importers, Sec. 9008 of the Patient Protection and Affordable Care Act (PPACA). Additional tax reporting information requirements as a result of Sec. 9006 of PPACA.
Health care reform issues including expansion of federal drug pricing programs (non Medicare/Medicaid) including 340B drug pricing program and TriCare drug formualry policies.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE, Treasury, Dept of
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2010 · third_quarter · Q3
Legislative Medicare reimbursement and federal Medicaid drug repbate program policies.
Health care reform issues; federal drug pricing programs (non Medicare or federal Medicaid) including 340B Drug Pricing Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2010 · second_quarter · Q2
Biosimilars; health care insurance reform issues; federal drug pricing programs (non-Medicaid/ non Medicare) including 340B Drug Pricing Program
Legislative Medicare/Medicaid reimbursement issues including part B reimbursement, Medicaid drug rebate policies
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2010 · first_quarter · Q1
Legislative Medicare/Medicaid reimbursement issues including Part B reimbursement, Medicaid drug rebate policies.
Biosimilars; health care insurance reform issues; federal drug pricing programs (non-Medicaid/ non-Medicare) including 340B Drug Pricing Program.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2009 · fourth_quarter · Q4
Biosimilars; health care insurance reform issues; federalk drug pricing programs (non-Medicaid/ non-Medicare).
Medicare/Medicaid reimbursement issues; congressional policy issues relating to Medicare/Medicaid
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2009 · third_quarter · Q3
Drug Safety; anti-counterfeiting and drug pedigree; follow-on biologics; health care insurance reform issues; Federal drug pricing programs (non medicaid/ non medicare).
Medicare/Medicaid reimbursement issues; congressional policy issues relating to Medicare/Medicaid
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2009 · second_quarter · Q2
Medicare reimbursement for plasma protein therapies; Medicaid drug rebate program
Drug safety; anti-counterfeiting and pedigree; follow-on biologics; health insurance reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2009 · first_quarter · Q1
Drug safety; anti-counterfeiting and drug pedigree; follow-on biologics; health insurance reform
Reimbursement for Medicare outpatient prospective payment system (OPPS) and Physician Fee Schedule; Medicaid Drug Rebate program
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2008 · fourth_quarter · Q4
Drug safety; anti-counterfeiting and drug pedigree; follow-on biologics; health insurance reform
Medicare reimbursement for plasma proteiin therapies; Medicaid drug rebate
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2008 · third_quarter · Q3
Drug safety; anticounterfeiting and drug pedigree; follow-on biologics; Insurance reform
Medicare reimbursement for plasma protein therapies; Medicaid drug rebate.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PLASMA PROTEIN THERAPEUTICS ASSOCIATION via PLASMA PROTEIN THERAPEUTICS ASSOCIATION
2008 · third_quarter · RR
Medicare reimbursement relating to plasma protein therapies; Federal Medicaid and Federal drug pricing programs; FDA drug safety legislation; and follow-on biologics.
Medicare reimbursement relating to plasma protein therapies; Federal Medicaid and Federal drug pricing programs; FDA drug safety legislation; and follow-on biologics.
Medicare reimbursement relating to plasma protein therapies; Federal Medicaid and Federal drug pricing programs; FDA drug safety legislation; and follow-on biologics.
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), SENATE, State, Dept of (DOS)
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. Educational meetings describing the plasma protein industry, and economic value, in the House and Senate. The proposed rule on International Pricing Index and Competitive Acquisition Program as well as Reference pricing and step therapy.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products. Legislation to extend the duration of the IVIG demonstration project.HR 3178, the Medicare Part B Improvement Act of 2017, provisions relating to the Medicare IVIG Demonstration Extension Act of 2017 and the Medicare Part B Infusion Services Temporary Transitional Payment Act. S. 1738, The Medicare Home Infusion Therapy Access Act of 2017 HR 3163 - Medicare Part B Home Infusion Services Temporary Transitional Payment Act, sections pertaining to payment of pharmacy fees. H.R.4724 - Medicare IVIG Access Enhancement Act - provisions relating to the development and funding for a demonstration project.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Protecting Americans from Tax Hikes (PATH) Act, sections pertaining to the Research and Development tax credit, and the Orphan Drug Tax Credit. HR 1.H.R.1 - An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018, sections pertaining to the Orphan Drug Tax Credit,
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Protecting Americans from Tax Hikes (PATH) Act, sections pertaining to the Research and Development tax credit, and the Orphan Drug Tax Credit.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Protecting Americans from Tax Hikes (PATH) Act, sections pertaining to the Research and Development tax credit, and the Orphan Drug Tax Credit.
The Affordable Care Act, provisions relating to essential health benefits and patient protections. HR 1628, The American Health Care Act, sections pertaining to essential health benefits, lifetime caps and affordability. Senate Better Care Reconciliation Act sections relating to essential health benefits, lifetime caps and affordability. HR 34, 21st Century Cures, relating to payment of pharmacy services for home infusion drugs in DME products.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE